The purpose is to fund clinical trials of products evaluating efficacy and/or safety in support of a new indication or change in labeling to address unmet needs in rare neurodegenerative diseases for children and adults. Through the support of collaborative, efficient, and/or innovative clinical trials, FDA expects to increase the number of approved treatments for rare neurodegenerative diseases and exert a broad and positive impact on rare disease drug development.

Government

• Special district governments
• Public and Indian housing authorities
• State governments
• Federally recognized Native American tribal governments
• City or township governments
• County governments

Nonprofit

• Nonprofits non-higher education with 501(c)(3)
• Other Native American tribal organizations
• Nonprofits non-higher education without 501(c)(3)

Education

• Public and state institutions of higher education
• Independent school districts
• Private institutions of higher education

Miscellaneous

• Unrestricted

Business

• Small businesses
• For-profit organizations other than small businesses